Subject(s)
Angioedema/virology , Coronavirus Infections/virology , Diabetes Mellitus, Type 2/virology , Hyperlipidemias/virology , Obesity/virology , Pneumonia, Viral/virology , Respiratory Insufficiency/virology , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Adult , Alanine/analogs & derivatives , Alanine/therapeutic use , Ampicillin/therapeutic use , Angioedema/immunology , Angioedema/physiopathology , Angioedema/therapy , Betacoronavirus/drug effects , Betacoronavirus/immunology , Betacoronavirus/pathogenicity , COVID-19 , Coronavirus Infections/immunology , Coronavirus Infections/physiopathology , Coronavirus Infections/therapy , Diabetes Mellitus, Type 2/immunology , Diabetes Mellitus, Type 2/physiopathology , Diabetes Mellitus, Type 2/therapy , Female , Humans , Hydroxychloroquine/therapeutic use , Hyperlipidemias/immunology , Hyperlipidemias/physiopathology , Hyperlipidemias/therapy , Intubation, Intratracheal , Obesity/immunology , Obesity/physiopathology , Obesity/therapy , Pandemics , Pneumonia, Viral/immunology , Pneumonia, Viral/physiopathology , Pneumonia, Viral/therapy , Respiration, Artificial , Respiratory Insufficiency/immunology , Respiratory Insufficiency/physiopathology , Respiratory Insufficiency/therapy , SARS-CoV-2 , Treatment OutcomeABSTRACT
Limited data are available on the clinical presentation and outcomes of coronavirus disease (COVID-19) patients in the United States hospitalized under normal-caseload or nonsurge conditions. We retrospectively studied 72 consecutive adult patients hospitalized with COVID-19 in 2 hospitals in the San Francisco Bay area, California, USA, during March 13-April 11, 2020. The death rate for all hospitalized COVID-19 patients was 8.3%, and median length of hospitalization was 7.5 days. Of the 21 (29% of total) intensive care unit patients, 3 (14.3% died); median length of intensive care unit stay was 12 days. Of the 72 patients, 43 (59.7%) had underlying cardiovascular disease and 19 (26.4%) had underlying pulmonary disease. In this study, death rates were lower than those reported from regions of the United States experiencing a high volume of COVID-19 patients.